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Background
The incidence of cutaneous malignant melanoma (MM)
continues to raise despite extensive prevention programs.
If localized disease can be cured, the prognosis of meta-
static melanoma is grim. Therefore, reliable methods to
detect patients at risk for disease progression are sought.
Field of tumor markers has captured attention because it
allows the first steps toward personalized medicine.
A positive tumor marker has a limited ability to correctly
detect all sick people, so it was proposed to simulta-
neously measure several markers in order to improve
their performance [1,2]. S100 and Melanoma Inhibitory
Activity (MIA) are most frequently used for monitoring
MM patients. Both proteins have a high specificity and
their expression correlates with body tumor burden [3].
Materials and methods
Between 2009 and 2013, we determined MIA and S100
serum concentration in 120 patients with non-meta-
static MM and 50 healthy donors, in order to compare
diagnostic and prognostic potential of these two bio-
markers. Both proteins were measured by a high sensi-
tivity ELISA method. For S100, a threshold of 100 ng/L
was accepted, as recommended by the kit manufacturer.
Using the ROC curve, we estimated a MIA cut-off level
of 9.4 ng/mL [4]. Patients were divided into 4 groups
according to markers concentrations: both markers
positive, both negative and one positive/one negative.
Median, disease free and overall survival (OS) were esti-
mated for each group.
Results
Survival varied depending on the number and type of
markers exceeding the cut-off. Median survival decreased
in this order: from S100/MIA negative group to MIA
negative/S100 positive, MIA positive/S100 negative,
S100/MIA positive group. It seems that a MIA value
above the cut-off has a negative impact on OS greater
than an increased S100 value. Two years OS was signifi-
cantly higher in MIA/S100 negative group compared
with MIA/S100 positive one (81%/51%; p=0.05). Further-
more, patients with a single positive marker had a higher
OS than those with both markers increased.
Conclusions
Simultaneous use of S100 and MIA increased sensitivity
of identifying MM patients irrespective of clinical stage.
Several tumor biomarkers determination affords selection
of those produced in high volume that will be further
used in patients follow-up. Measuring both MIA and
S100 allows outlining of an intermediate prognosis group
of patients, represented by those with a single positive
marker, who have a lower risk of relapse and death than
those with both positive markers.
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